Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: A systematic review and meta-analysis

International Journal of Infectious Diseases

Volumn 15, Issue 3, 2011, Pages

  Chen, Tun Chieh ^a,b   Lu, Po Liang ^a,b   Lin, Chun Yu ^a,b   Lin, Wei Ru ^a   Chen, Yen Hsu ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Fluoroquinolone; Meta analysis; Resistance; Tuberculosis

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOSUFLOXACIN; TROVAFLOXACIN;

ARTICLE; BACTERIAL STRAIN; BIOSIS; CINAHL; COCHRANE LIBRARY; COMMUNITY ACQUIRED PNEUMONIA; DELAYED DIAGNOSIS; EMBASE; HIGH RISK PATIENT; HUMAN; LUNG TUBERCULOSIS; MEDLINE; META ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRESCRIPTION; SYSTEMATIC REVIEW;

DATABASES, FACTUAL; DELAYED DIAGNOSIS; FLUOROQUINOLONES; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 79952103166     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.11.008     Document Type: Article

References (31)

1. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-72.
2. Hsueh P.R. Should fluoroquinolones be first-line antibiotics in the treatment of community-acquired pneumonia in areas with high incidence of tuberculosis?. J Microbiol Immunol Infect 2007, 40:386-387.
3. KiaNoury D., Timpone J., Yeager H. Can administration of a fluoroquinolone delay diagnosis of pulmonary tuberculosis?. Int J Tuberc Lung Dis 2000, 4:1092.
4. Ginsburg A.S., Woolwine S.C., Hooper N., Benjamin W.H., Bishai W.R., Dorman S.E., et al. The rapid development of fluoroquinolone resistance in M. tuberculosis. N Engl J Med 2003, 349:1977-1978.
5. Ang D., Hsu A.A., Tan B.H. Fluoroquinolones may delay the diagnosis of tuberculosis. Singapore Med J 2006, 47:747-751.
6. Avnon L.S., Jotkowitz A., Smoliakov A., Flusser D., Heimer D. Can the routine use of fluoroquinolones for community-acquired pneumonia delay the diagnosis of tuberculosis? A salutary case of diagnostic delay in a pilgrim returning from Mecca. Eur J Intern Med 2006, 17:444-446.
7. Grupper M., Potasman J. Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: an instructive case. Am J Med Sci 2008, 335:141-144.
8. Osawa N., Sakaguchi M., Sugimoto T., Isshiki K., Kanasaki M., Nishio T., et al. Does empiric treatment with fluoroquinolones delay the diagnosis of tuberculosis in patients with hemodialysis?. Hemodial Int 2008, 12:499-500.
9. Singh A. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity. Clin Infect Dis 2007, 45:133.
10. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Ann Intern Med 2009, 151:264-269. the PRISMA Group.
11. Dooley K.E., Golub J., Goes F.S., Merz W.G., Sterling T.R. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002, 34:1607-1612.
12. Ginsburg A.S., Hooper N., Parrish N., Dooley K.E., Dorman S.E., Booth J., et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003, 37:1448-1452.
13. Golub J.E., Bur S., Cronin W.A., Gange S., Sterling T.R., Oden B., et al. Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2005, 9:392-397.
14. Yoon Y.S., Lee H.J., Yoon H.I., Yoo C.G., Kim Y.W., Han S.K., et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005, 9:1215-1219.
15. Wang J.Y., Hsueh P.R., Jan I.S., Lee L.N., Liaw Y.S., Yang P.C., et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006, 61:903-908.
16. Wang J.Y., Lee L.N., Lai H.C., Wang S.K., Jan I.S., Yu C.J., et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother 2007, 59:860-865.
17. Park I.N., Hong S.B., Oh Y.M., Lim C.M., Lee S.D., Lew W.J., et al. Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 2007, 11:319-324.
18. Devasia R.A., Blackman A., Gebretsadik T., Griffin M., Shintani A., May C., et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009, 180:365-370.
19. Long R., Chong H., Hoeppner V., Shanmuganathan H., Kowalewska-Grochowaska K., Shandro C., et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009, 48:1354-1360.
20. Woodhead M., Blasi F., Ewig S., Huchon G., Leven M., Ortqviste A., et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005, 26:1138-1180.
21. Levy M.L., Le Jeune I., Woodhead M.A., Macfarlaned J.T., Lim W.S. Primary care summary of the British Thoracic Society Guidelines for the management of community acquired pneumonia in adults: 2009 update. Endorsed by the Royal College of General Practitioners and the Primary Care Respiratory Society UK. Prim Care Respir J 2010, 19:21-27. British Thoracic Society Community Acquired Pneumonia in Adults Guideline Group.
22. Waterer G.W., Grayson M.L. The United States guidelines for the management of community-acquired pneumonia and their relevance to Australasia. Intern Med J 2007, 37:789-791.
23. Craig S.E., Bettinson H., Sabin C.A., Gillespie S.H., Lipman M.C.I. Think TB! Is the diagnosis of pulmonary tuberculosis delayed by the use of antibiotics?. Int J Tuberc Lung Dis 2009, 13:208-213.
24. Balabanova Y., Fedorin I., Kuznetsov S., Graham C., Ruddy M., Atun R., et al. Antimicrobial prescribing patterns for respiratory diseases including tuberculosis in Russia: a possible role in drug resistance?. J Antimicrob Chemother 2004, 54:673-679.
25. Ginsburg A.S., Sun R., Calamita H., Scott C.P., Bishai W.R., Grosset J.H. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob Agents Chemother 2005, 49:3977-3979.
26. Gumbo T., Louie A., Deziel M.R., Drusano G.L. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother 2005, 49:3178-3181.
27. Chang K.C., Leung C.C., Yew W.W., Lau T.Y., Leung W.M., Tam C.M., et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?. Eur J Respir 2010, 35:606-613.
28. Ginsburg A.S., Grosset J.H., Bishai W.R. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003, 3:432-442.
29. Storla D.G., Yimer S., Bjune G.A. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 2008, 8:15.
30. Lin C.Y., Lin W.R., Chen T.C., Lu P.L., Huang P.M., Tsai Z.R., et al. Why is in-hospital diagnosis of pulmonary tuberculosis delayed in southern Taiwan?. J Formos Med Assoc 2010, 109:269-277.
31. Webster D., Long R., Shandro C., Pettipas J., Lebianc J., Davidson R., et al. Fluoroquinolone resistance in renal isolates of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2010, 14:217-222.